Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.67 |
| ▸ | CA2 | P00918 | 3/20 | 0.67 |
| ▸ | CA7 | P43166 | 3/20 | 0.67 |
| ▸ | CA9 | Q16790 | 3/20 | 0.67 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.67 |
| ▸ | ESR1 | P03372 | 5/20 | 0.62 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.62 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5512748 | 0.94 | CA1 (0.76) | CA1CA2CA7CA9CA14 | |
| SCHEMBL19135758 | 0.91 | CA1 (0.62) | CA1CA2CA7CA9CA14 | |
| SCHEMBL16523571 | 0.91 | CA1 (0.61) | CA1CA2CA7CA9CA14 | |
| SCHEMBL10680869 | 0.87 | CA1 (0.70) | CA1CA2CA7CA9CA14 | |
| SCHEMBL3056380 | 0.85 | CA1 (0.68) | CA1CA2CA7CA9CA14 | |
| SCHEMBL8243015 | 0.83 | PDE4B (0.56) | CA1CA2CA7CA9CA14 | |
| SCHEMBL30199245 | 0.82 | ESR2 (0.68) | CA1CA2CA7CA9CA14 | |
| SCHEMBL1648634 | 0.82 | ESR2 (0.68) | CA1CA2CA7CA9CA14 | |
| SCHEMBL3895820 | 0.81 | ESR2 (0.66) | CA1CA2CA7CA9CA14 | |
| SCHEMBL31189089 | 0.80 | CA1 (0.62) | CA1CA2CA7CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7256201-B2 | Selective estrogen receptor-β ligands | ASTRAZENECA AB (SE) | 2007-08-14 | — | — | US | disclosed |
| US-20050101584-A1 | Selective estrogen receptor-beta ligands | ASTRAZENECA AB (SE) | 2005-05-12 | — | — | US | disclosed |
| EP-1341765-A1 | THERAPEUTIC COMPOUNDS | AstraZeneca AB (SE) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002046164-A1 | THERAPEUTIC COMPOUNDS | ASTRAZENECA AB (SE) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101584-A1 | Selective estrogen receptor-beta ligands | ESR2, ESRRA, ESRRB | CA1 3708/4885CA2 4743/4885CA7 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.